Showing results (51-60 of 75) with videos related to

Sort By:
Pageof 8
American Heart Journal|June 23, 2026
DOAC Score Among Patients Receiving Vitamin K AntagonistsRahul Aggarwal, Christian T Ruff, Michael G Palazzolo, et al.
Annals of Medicine|April 5, 2021
Risk profile, antithrombotic treatment and clinical outcomes of patients in Nordic countries with atrial fibrillation - results from the GARFIELD-AF registryMarita Knudsen Pope, Dan Atar, Arne Svilaas, et al.
Open Heart|July 2, 2024
Impact of patient selection in clinical trials: application of ROCKET AF and ARISTOTLE criteria in GARFIELD-AFJelle C L Himmelreich, Saverio Virdone, John Camm, et al.
Heart (British Cardiac Society)|June 28, 2020
Patterns of oral anticoagulation use with cardioversion in clinical practiceKyle Geurink, DaJuanicia Holmes, Michael D Ezekowitz, et al.
American Heart Journal|March 18, 2020
Risk of major cardiovascular and neurologic events with obstructive sleep apnea among patients with atrial fibrillationFrederik Dalgaard, Rebecca North, Karen Pieper, et al.
European Journal of Internal Medicine|August 26, 2025
Sex differences in venous thromboembolism outcomes: findings from the GARFIELD-VTE registryPaolo Prandoni, Meg Fluharty, Sebastian Schellong, et al.
The American Journal of Medicine|November 2, 2023
Clinical Outcomes in Older Patients with Atrial Fibrillation: Insights from the GARFIELD-AF RegistrySamuel Z Goldhaber, Jean-Pierre Bassand, A John Camm, et al.
Circulation|July 23, 2003
Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular diseaseEric J Topol, Donald Easton, Robert A Harrington, et al.
The Lancet. Haematology|July 2, 2022
Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trialFrank Cools, Saverio Virdone, Jitendra Sawhney, et al.
Plos One|January 26, 2018
Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillationJean-Pierre Bassand, Gabriele Accetta, Wael Al Mahmeed, et al.
Pageof 8